Blog
RSS FeedPosted by Michael Wonder on 04 Jan 2026
Bayer Korea's Eylea pre-filled syringe 8 mg to receive health insurance coverage
30 December 2025 - Bayer Korea announced that its Eylea pre-filled syringe 8 mg will be covered by health insurance ...
Posted by Michael Wonder on 04 Jan 2026
GC Biopharma’s Livmarli listed for national health insurance coverage for Alagille syndrome
2 January 2026 - GC Biopharma said Livmarli (maralixibat chloride), a treatment for Alagille syndrome, has been officially listed on ...
Posted by Michael Wonder on 28 Dec 2025
Drug makers push back against government’s generic price cut plan
28 December 2025 - Pharma industry warns lower generic prices will curb R&D, health officials cite unchanged pricing since 2012. ...
Posted by Michael Wonder on 25 Dec 2025
Korea to expand Keytruda reimbursement to 11 new cancer uses starting 2026
24 December 2025 - Korea’s national health insurance program will broaden reimbursement for MSD’s blockbuster PD-1 inhibitor Keytruda in a ...
Posted by Michael Wonder on 24 Dec 2025
Pharma industry pushes back against generic drug price cuts
23 December 2025 - South Korea's pharmaceutical and biotech industry has begun mounting a coordinated backlash against the government's plan ...
Posted by Michael Wonder on 24 Dec 2025
Lilly’s Jaypirca wins Korea reimbursement for relapsed mantle cell lymphoma
10 October 2025 - Eli Lilly’s Jaypirca (pirtobrutinib) has been added to Korea’s national health insurance effective Oct. 1 for ...
Posted by Michael Wonder on 24 Dec 2025
Korea pharma groups warn price reform will cut 3.6 trillion won and cost jobs
22 December 2025 - Pharma associations form emergency committee to demand delay and joint review of planned generic price cuts. ...
Posted by Michael Wonder on 02 Dec 2025
Korea eases path to breakthrough drugs with flexible ICER rules
1 December 2025 - The Government has unveiled a large-scale overhaul of the health insurance drug pricing system, proposing flexible ...
Posted by Michael Wonder on 02 Dec 2025
GSK’s Jemperli now standard in endometrial cancer as reimbursement expands to first-line therapy
1 December 2025 - GSK’s Jemperli has secured its position as a standard treatment option in endometrial cancer following Korea’s ...
Posted by Michael Wonder on 30 Nov 2025
Korea launches sweeping drug pricing reform to curb generic dominance
29 November 2025 - The Government will launch a large scale overhaul of the drug pricing system starting in the ...
Posted by Michael Wonder on 12 Nov 2025
AstraZeneca’s Imfinzi, Imjudo, and Ultomiris clear reimbursement panel review
7 November 2025 - AstraZeneca's anti-PD-L1 immune checkpoint inhibitor Imfinzi (durvalumab), the anti-CTLA-4 immune checkpoint inhibitor Imjudo (tremelimumab), and the ...
Posted by Michael Wonder on 07 Nov 2025
Gilead's Vemlidy now reimbursed as initial therapy for chronic hepatitis B in Korea
5 November 2025 - Gilead Sciences Korea announced that, starting this month, Vemlidy (tenofovir alafenamide hemifumarate) will be covered under ...
Posted by Michael Wonder on 05 Nov 2025
AstraZeneca’s Ultomiris gets insurance benefits for neuromyelitis optica spectrum disorders
4 November 2025 - AstraZeneca Korea announced on Monday that the C5 complement inhibitor Ultomiris (ravulizumab) has been covered by ...
Posted by Michael Wonder on 20 Oct 2025
Ipsen’s Bylvay launches in Korea with national coverage for a rare childhood liver disease
20 October 2025 - Ipsen Korea has rolled out Bylvay (odevixibat) in Korea with national health insurance coverage, giving children ...
Posted by Michael Wonder on 01 Oct 2025
Imfinzi’s bid for coverage faces Keytruda’s double-edged impact in Korea
30 September 2025 - AstraZeneca's immuno-oncology drug Imfinzi (durvalumab) is attempting to expand its reimbursement coverage, but its competitor, MSD's ...